Responding to the Call to Action: Framework to Accelerate Clinical Data Generation for Antiretroviral Use in Pregnant Individuals with HIV

Vani Vannappagari, Annemiek de Ruiter(ViiV Healthcare (Spain)), Nneka Nwokolo(ViiV Healthcare (United Kingdom)), Nassrin Payvandi(ViiV Healthcare (United Kingdom)), Scott McCallister, Kimberly Smith, Dinesh Stanislaus(GlaxoSmithKline (United States)), Beth Romach(Triangle), H Garges(Triangle), Christine Lampkin, Mark Bush(Research Triangle Park Foundation), Ralph DeMasi(Janssen (Belgium)), Charlotte Root(ViiV Healthcare (United Kingdom)), Farzaneh Salem(Age UK), Sebastian Moreira(South College), Ana M. Puga(Children's Diagnostic & Treatment Center)
Infectious Diseases and Therapy
May 22, 2024
10.1007/s40121-024-00993-4
Cited by 4

Related Papers

Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
|The Lancet|2019|1k
Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
|New England Journal of Medicine|2003|653
Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen
|The Lancet|1996|631
Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006
|AIDS|2008|582
Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000–2011
|AIDS|2014|397